Bullish
Johnson & Johnson's stock extends 54% rally as Q2 2026 drug shift lifts outlook
Johnson & Johnson's stock has surged over 50% in the past year, driven by a strategic shift towards newer immunology drugs and an increased full-year sales forecast. The company's Q2 2026 results highlighted a significant rise in TREMFYA sales, offsetting declines in older drugs like STELARA. This positive momentum has bolstered investor confidence, with the stock trading near record highs.
Key points
- TREMFYA sales reached $2 billion in Q2 2026, a 71% increase year-over-year, contributing to a 54% stock rally.
- The company raised its 2026 operational sales guidance to a midpoint of $100.6 billion, reflecting strong performance in its pharmaceutical segment.
- Institutional investors, such as Continuum Advisory LLC, have adjusted their holdings, with a 47.4% reduction in their position during Q2 2026.
- The FDA approved IMAAVY (nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia, expanding J&J's immunology portfolio.
Sources
- Johnson & Johnson stock extends 54 percent rally as Q2 2026 drug shift lifts outlookAD HOC NEWS · August 29, 2026
- Continuum Advisory LLC Sells 4,074 Shares of Johnson & Johnson $JNJAmerican Banking News · August 29, 2026
- FDA approves IMAAVY (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsComtex · August 24, 2026
AI-generated from public news sources. Not financial advice.
